Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
56 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Anaplastic Astrocytoma - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Anaplastic Astrocytoma - Pipeline Review, H2 2014', provides an overview of the Anaplastic Astrocytoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Anaplastic Astrocytoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anaplastic Astrocytoma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Anaplastic Astrocytoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Anaplastic Astrocytoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Anaplastic Astrocytoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Anaplastic Astrocytoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Anaplastic Astrocytoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Anaplastic Astrocytoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Anaplastic Astrocytoma Overview 6 Therapeutics Development 7 Pipeline Products for Anaplastic Astrocytoma - Overview 7 Pipeline Products for Anaplastic Astrocytoma - Comparative Analysis 8 Anaplastic Astrocytoma - Therapeutics under Development by Companies 9 Anaplastic Astrocytoma - Therapeutics under Investigation by Universities/Institutes 10 Anaplastic Astrocytoma - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Unknown Stage Products 13 Anaplastic Astrocytoma - Products under Development by Companies 14 Anaplastic Astrocytoma - Products under Investigation by Universities/Institutes 15 Anaplastic Astrocytoma - Companies Involved in Therapeutics Development 16 Sanofi 16 Peregrine Pharmaceuticals, Inc. 17 TVAX Biomedical, Inc. 18 Oncovir, Inc. 19 EirGen Pharma Ltd. 20 Tocagen Inc. 21 Anaplastic Astrocytoma - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Combination Products 23 Assessment by Target 24 Assessment by Mechanism of Action 26 Assessment by Route of Administration 28 Assessment by Molecule Type 30 Drug Profiles 32 Eir-060 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 TVI-Brain-1 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 leflunomide - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Cell Therapy for Oncology - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Poly-ICLC - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 vocimagene amiretrorepvec + flucytosine ER - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Engineered Herpes Simplex Virus Expressing Human IL-12 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Cotara - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Anaplastic Astrocytoma - Recent Pipeline Updates 47 Anaplastic Astrocytoma - Dormant Projects 51 Anaplastic Astrocytoma - Discontinued Products 52 Anaplastic Astrocytoma - Product Development Milestones 53 Featured News & Press Releases 53 Feb 29, 2012: Antisense Pharma Terminates Phase III High Grade Glioma Trial And Expands First-Line Treatment With Trabedersen 53 Jan 10, 2012: EirGen Pharma Registers Oncology Product Eir-060 with FDA 53 Jun 06, 2011: CTI Announces Interim Results Of Phase II Study Of OPAXIO In Combination With Temozolomide And Radiotherapy In Brain Tumors 53 Jan 08, 2007: Hana Biosciences Announces 2007 Corporate Goals 54 Jun 09, 2006: Hana Biosciences Receives Orphan Drug Designation For Ropidoxuridine (IPdR), For The Treatment Of Malignant Glioma 54 Appendix 55 Methodology 55 Coverage 55 Secondary Research 55 Primary Research 55 Expert Panel Validation 55 Contact Us 56 Disclaimer 56
List of Tables Number of Products under Development for Anaplastic Astrocytoma, H2 2014 7 Number of Products under Development for Anaplastic Astrocytoma - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Number of Products under Investigation by Universities/Institutes, H2 2014 10 Comparative Analysis by Late Stage Development, H2 2014 11 Comparative Analysis by Clinical Stage Development, H2 2014 12 Comparative Analysis by Unknown Stage Development, H2 2014 13 Products under Development by Companies, H2 2014 14 Products under Investigation by Universities/Institutes, H2 2014 15 Anaplastic Astrocytoma - Pipeline by Sanofi, H2 2014 16 Anaplastic Astrocytoma - Pipeline by Peregrine Pharmaceuticals, Inc., H2 2014 17 Anaplastic Astrocytoma - Pipeline by TVAX Biomedical, Inc., H2 2014 18 Anaplastic Astrocytoma - Pipeline by Oncovir, Inc., H2 2014 19 Anaplastic Astrocytoma - Pipeline by EirGen Pharma Ltd., H2 2014 20 Anaplastic Astrocytoma - Pipeline by Tocagen Inc., H2 2014 21 Assessment by Monotherapy Products, H2 2014 22 Assessment by Combination Products, H2 2014 23 Number of Products by Stage and Target, H2 2014 25 Number of Products by Stage and Mechanism of Action, H2 2014 27 Number of Products by Stage and Route of Administration, H2 2014 29 Number of Products by Stage and Molecule Type, H2 2014 31 Anaplastic Astrocytoma Therapeutics - Recent Pipeline Updates, H2 2014 47 Anaplastic Astrocytoma - Dormant Projects, H2 2014 51 Anaplastic Astrocytoma - Discontinued Products, H2 2014 52
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.